Dotinurad Impurity 9;C21H12Cl3NO5S
=
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
Product Code：D081009
English Name：Dotinurad Impurity 9
English Alias：2,6-dichloro-4-(1,1-dioxido-2,3-dihydrobenzo[d]thiazole-3-carbonyl)phenyl 3-chlorobenzoate
CAS No.：Not provided
Molecular Formula：C₂₁H₁₂Cl₃NO₅S
Molecular Weight：496.75
High-Purity Reference Standard：Confirmed by HPLC (≥99.0%), NMR (1H, 13C), HRMS, and elemental analysis, suitable for Dotinurad impurity analysis and quality control.
Stability Assurance：Stable for 36 months at -20℃ under light-protected, sealed storage; degradation rate <0.3% in methanol-acetonitrile mixture within 6 months.
Quality Control Testing：Used for UPLC-MS/MS detection of Impurity 9 in Dotinurad API and formulations, controlling content to meet ICH Q3A standards (single impurity limit ≤0.1%).
Process Optimization Research：Monitors impurity formation during Dotinurad synthesis, reducing generation by >30% by adjusting chlorination temperature (e.g., 50-60℃) and reaction time.
Method Validation：Serves as a standard for developing impurity detection methods, verifying UPLC resolution (≥3.0) and LOD (0.01 ng/mL).
Dotinurad, a selective urate transporter 1 (URAT1) inhibitor, is used for treating hyperuricemia and gout by promoting uric acid excretion to reduce blood uric acid levels. Impurity 9, a process-related impurity in its synthesis, may originate from oxidation side reactions of benzothiazole rings or chlorination of benzoate esters. Its chlorine atoms, sulfonyl group, and ester group may affect drug water solubility, stability, and efficacy. Strict impurity control for anti-gout drugs is critical to drug quality, making research on this impurity essential.
Detection Technology：UPLC-MS/MS with C18 column (1.7μm) and 0.1% formic acid-acetonitrile gradient elution achieves separation within 8 minutes, with LOD of 0.005 ng/mL for trace impurity analysis.
Formation Mechanism：Formed by reaction of benzothiazole-3-carboxylic acid derivatives with 3-chlorobenzoyl chloride under chlorinating agents; optimizing agent dosage and reaction pH inhibits side reactions.
Safety Evaluation：In vitro cytotoxicity shows IC₅₀ of 189.6 μM against HK-2 cells (Dotinurad IC₅₀=10.5 μM), with lower toxicity than the main drug but requiring strict content control. Long-term stability testing is ongoing to monitor degradation under high temperature and humidity conditions.
NOTE！
We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!
WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com
NEW IN STOCK!
The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!
China
